ReviewTrends in cardiovascular medicine2017
Cardiovascular disease in patients with HIV.
Review in Trends in cardiovascular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence and risk factors of cardiovascular disease among people living with HIV in the Asia-Pacific region: a systematic review.BMC public health · 2023Pooled it
- Gut microbiome in people living with HIV is associated with impaired thiamine and folate syntheses.Microbial pathogenesis · 2021Pooled it
- Symptoms and Comorbidities Differ Based on Race and Weight Status in Persons with HIV in the Northern United States: a Cross-Sectional Study.Journal of racial and ethnic health disparities · 2023Trial
- Effect of atorvastatin on subclinical atherosclerosis in virally-suppressed HIV-infected patients with CMV seropositivity: a randomized double-blind placebo-controlled trial.F1000Research · 2021Trial
- Association between HIV infection and arterial stiffness: A population-based cross-sectional study from Rakai, South Western Uganda.Atherosclerosis plus · 2026Article
- Predictors of cardiovascular disease among people living with HIV in northern Nigeria.Research square · 2026Article
- Article
- Article
- Adverse childhood experiences, sexual orientation-related victimization, and cardiovascular disease risk among men with and without HIV.AIDS (London, England) · 2025Article
- Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.International journal of molecular sciences · 2025Review
- Review
- [Capillaroscopy, microangiopathy, and HIV. Descriptive study of capillaroscopy findings in HIV positive patients].Anales del sistema sanitario de Navarra · 2022Article
- Formation and Cellular Impact of Cholesterol Crystals in Health and Disease.Advanced biology · 2021Review
- Article
- Metabolic Syndrome Prevalence and Cardiovascular Risk Assessment in HIV-Positive Men with and without Antiretroviral Therapy.Medicina (Kaunas, Lithuania) · 2021Article
- Contributory role of ART in the development of non-AIDS comorbidities in asymptomatic PLWHA.Journal of applied biomedicine · 2021Article
- Visual Impairment and Eye Diseases in HIV-infected People in the Antiretroviral Therapy (ART) Era in Rakai, Uganda.Ophthalmic epidemiology · 2021Article
- Cardiovascular disease risk and its determinants in people living with HIV across different settings in South Africa.HIV medicine · 2020Article
- Deconstructing Syndemics: The Many Layers of Clustering Multi-Comorbidities in People Living with HIV.International journal of environmental research and public health · 2020Article
- Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial.Journal of clinical medicine · 2020Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the progressive increase in life expectancy of HIV-positive patient, thanks to "highly active antiretroviral therapy" (HAART), new comorbidities, and especially cardiovascular diseases (CVDs) are emerging as an important concern. An increased risk of coronary artery disease, often in a younger age, has been observed in this population. The underlying pathophysiology is complex and partially still unclear, with the interaction of viral infection-and systemic inflammation-antiretroviral therapy and traditional risk factors. After an accurate risk stratification, primary prevention should balance the optimal HAART to suppress the virus-avoiding side-effects-the intervention on life-style and the treatment of traditional risk factors (hypertension, dyslipidemia, and diabetes). Also the management after a cardiovascular event is challenging: revascularization strategies-both percutaneous and surgical-are valuable options, keeping in mind the higher rates of recurrent events, and caution is essential to avoid drug-drug interactions. Large evidence-based data on HIV-infected patients are still lacking, and recommendations often follow those of general population. Therefore we performed a comprehensive evaluation of the literature to analyze the current knowledge on CVD's prevalence, prevention and treatment in HIV-infected patients.
Indexed as
Identifiers
28779949What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.